AMENDMENTS TO THE CLAIMS

Docket No.: 60261(49946)

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-125 (Canceled)

- 126. (Currently amended) A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with an isolated polypeptide selected from the group consisting of:
- i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO:2;
- ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO:11;
 - iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;
- iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO:2; and
- v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO:2.
- 127. (Previously presented) The method of claim 126, wherein the polypeptide is recombinant.
- 128. (Currently amended) The method of claim 126 or 127, wherein said <u>bacterial cell is</u> <u>present in a sample</u>, and the method identifies <u>polypeptide</u> is used in therapy, diagnosis or <u>prophylaxis of</u> a microbial infection <u>in the sample</u>.
- 129. (Currently amended) The method of claim 128, wherein the <u>cell is present in a patient is immunotherapy</u>.
- 130. (Previously presented) The method of claim 126 or 127, wherein said polypeptide is in a pharmaceutically acceptable carrier suitable for local or systemic administration.

131. (Previously presented) The method of claim 126 or 127, wherein the polypeptide is in unit dosage form.

- 132. (Withdrawn) A pharmaceutical composition for resuscitating dormant, moribund or latent bacterial cells comprising,
 - a therapeutically effective amount of a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2
 - ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;
 - iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;
 - iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and
 - v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2, and a pharmaceutically acceptable carrier therefor.
 - 133. (Withdrawn) The composition of claim 132, wherein the composition is a vaccine.
- 134. (Withdrawn) The composition of claim 133, wherein the vaccine is a live vaccine comprising an attenuated microbe.
- 135. (Withdrawn) A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with an antibody or functional fragment thereof that binds a polypeptide selected from the group consisting of:
- i) a polypeptide comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2
- ii) a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;
 - iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;

- iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and
- v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

Docket No.: 60261(49946)

- 136. (Withdrawn) The method of claim 135, wherein the antibody is suitable for use in therapy, diagnosis, or prophylaxis of a microbial infection.
 - 137. (Withdrawn) The method of claim 136, wherein the therapy is an immunotherapy.
- 138. (Withdrawn) The method of claim 136, wherein the antibody is in a pharmaceutically acceptable carrier suitable for local or systemic administration.
 - 139. (Withdrawn) The method of claim 136, wherein the antibody is in unit dosage form. 140-143. (Canceled)
- 144. (Currently amended) A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with a cell strain expressing a nucleic acid encoding a polypeptide comprising a sequence selected from the group consisting of:
- i) a polypeptide comprising at least 50%-identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2;
- ii)—a polypeptide comprising at least 50% homology with amino acid residues 224 to 318 of SEQ ID NO: 11;
 - iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 43;
- iv) a polypeptide comprising at least 20% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2; and
- v) a polypeptide homologue, allelic form, species variant or mutein comprising at least 50% identity or homology with amino acid residues 117 to 184 of SEQ ID NO: 2.

145-147. (Canceled)

148. (New) The method of claim 126, wherein the isolated polypeptide comprises at least 90% identity with amino acid residues 117 to 184 of SEQ ID NO:2.

Application No. 09/445,289 Amendment dated August 1, 2007

Reply to Office Action of February 1, 2007

149. (New) The method of claim 126, wherein the isolated polypeptide comprises at least 95% identity with amino acid residues 117 to 184 of SEQ ID NO:2.

Docket No.: 60261(49946)

- 150. (New) The method of claim 126, wherein the isolated polypeptide comprises amino acid residues 117 to 184 of SEQ ID NO:2.
- 151. (New) A method for stimulating the growth of a bacterial cell comprising, contacting the bacterial cells with the isolated polypeptide of SEQ ID NO:2.
- 152. (New) A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with an isolated *M. luteus* RF-factor polypeptide (SEQ ID NO:35), thereby resuscitating the dormant, moribund, or latent bacterial cells.
- 153. (New) A method for resuscitating dormant, moribund or latent bacterial cells comprising, contacting the bacterial cells with an isolated polypeptide comprising at least 85% identity with SEQ ID NO:2.
- 154. (New) The method of claim 153, wherein the polypeptide comprises at least 90% identity with SEQ ID NO:2.
- 155. (New) The method of claim 154, wherein the polypeptide comprises at least 95% identity with SEQ ID NO:2.
- 156. (New) The method of claim 155, wherein the polypeptide consists of SEQ ID NO:2.